Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZX-29 is a potent and selective inhibitor of ALK(IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively), and also induces protective autophagy and has antitumor effect.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 663.00 | |
50 mg | In stock | $ 945.00 | |
100 mg | In stock | $ 1,280.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 317.00 |
Description | ZX-29 is a potent and selective inhibitor of ALK(IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively), and also induces protective autophagy and has antitumor effect. |
Targets&IC50 | ALK:2.1 nM , ALK L1196M:1.3 nM , ALK G1202R:3.9 nM |
In vitro | ZX-29 dose-dependently inhibits colony formation of NCI-H2228 cells. With an increase in ZX-29 concentration, the cell density decreased gradually, and the cells lost their normal morphology and become sharp and slender. In NCI-H2228 cells, ZX-29 (10 nM; 0-48 hours) inhibits the proliferation of and arrests the cells in G1 phase. ZX-29 (0-81 nM; 24-72 hours) treatment resulted in a decrease in the viability with time and dose. ZX-29 (10 nM; 24 hours) treatment causes typical signs of autophagy and the formation of autophagosomes and enhances the expression level of LC3 and Beclin1. ZX-29 (20 nM; 0-48 hours) treatment significantly increases the mRNA level of CHOP[1]. |
In vivo | In a mouse xenograft model, ZX-29 treatment suppresses tumor growth[1]. |
Molecular Weight | 518.03 |
Formula | C23H28ClN7O3S |
CAS No. | 2254805-62-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 42.5 mg/mL (82.04 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZX-29 2254805-62-2 Angiogenesis Tyrosine Kinase/Adaptors ALK arrest antitumor ZX29 Resistance Anaplastic lymphoma kinase Bcl-2 Apoptosis Inhibitor CD246 p-Akt caspase-3 endoplasmic inhibit CHOP Anaplastic lymphoma kinase (ALK) ALK tyrosine kinase receptor ERS Cluster of differentiation 246 Autophagy reticulum p-STAT3 ZX 29 inhibitor